Please login to the form below

Not currently logged in
Email:
Password:

lupus

This page shows the latest lupus news and features for those working in and with pharma, biotech and healthcare.

BMS psoriasis drug hits the mark in phase II

BMS psoriasis drug hits the mark in phase II

BMS also has phase II studies of the drug ongoing in other indications including systemic lupus erythematosus and Crohn's disease.

Latest news

More from news
Approximately 8 fully matching, plus 99 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Similarly, Novartis has enjoyed 31.7% growth thanks to another psoriasis/psoriatic arthritis treatment - Cosentyx - while GSK’s lupus therapy, Benlysta, has helped it increase immunology revenues by almost 45%.”.

  • Opening up innovation Opening up innovation

    Leading this is Benlysta (belimumab), which in 2011 became the first new treatment for lupus to be approved in over 50 years and is being investigated for other auto antibody-dependent

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    750. Hanmi / Eli Lilly. Licence and collaboration. Phase 1 BTK inhibitor for treatment of lupus. ... 230. SuppreMol / Baxter. Company acquisition. Biologic immuno-regulatory pipeline with phase 2 lead product for treatment of ITP and lupus.

  • Building a business that is lean and specialised Building a business that is lean and specialised

    The company was Human Genome Sciences and its acquirer, GlaxoSmithKline, had its eye on gaining full control of Benlysta (belimumab), the lupus product that the two had been co-marketing.

  • The distressing impact of rare diseases The distressing impact of rare diseases

    A UK patient with mixed connective tissue disease (an autoimmune rare disease which has the signs and symptoms of lupus, scleroderma, polymyositis, and rheumatoid arthritis) stated: “ Getting a correct diagnosis was

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics